Charles River Laboratories International, Inc.· CRL
🇺🇸 US · LargeSP500NYSE
- Price
- $288.50
- Day
- -1.65%
- Mkt Cap
- $13.90B
- 52W Range
- $144.26 – $303.31
- Volume
- 735.6K
- Beta
- 1.41
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Read full article
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Read full article
Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares
Read full article
According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.
Read full article
Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company's stock, valued at approximately $459,000. A
Read full article
CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
Read full article
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Read full article
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC's next-generation multivalent.
Read full article
On June 30, 2026, John Rogers (Trades, Portfolio), founder of Ariel Investment, LLC, increased the firm's stake in Core Laboratories Inc (NYSE: CLB) by 904,557 s
Read full article
On June 30, 2026, John Rogers (Trades, Portfolio), through Ariel Investment, LLC, executed a reduction of the firm's position in Lindblad Expeditions Holdings I
Read full article
On June 30, 2026, John Rogers (Trades, Portfolio), through Ariel Investment, LLC, executed a significant reduction in the firm's position in Sphere Entertainmen
Read full article